Veradermics Reports Positive Phase 2 Results for Oral VDPHL01 in Female Pattern Hair Loss, Supporting Ongoing Pivotal Development
Veradermics, Incorporated, a late-stage biopharmaceutical company focused on developing innovative therapies for pattern hair loss, has announced positive topline results from its open-label Phase 2 Study ‘207’ evaluating VDPHL01, the company’s proprietary extended-release oral minoxidil formulation, in women with mild-to-moderate female pattern hair loss.
The study demonstrated encouraging improvements in hair growth, patient-reported outcomes, and investigator assessments after six months of treatment, while also showing a favorable safety profile. According to Veradermics, the findings strengthen confidence in the ongoing registration-directed Phase 2/3 Study ‘306’, which is designed to support regulatory approval of VDPHL01 for female pattern hair loss.
If ultimately approved by the U.S. Food and Drug Administration (FDA), VDPHL01 could become the first FDA-approved oral prescription therapy specifically indicated for female pattern hair loss, addressing a significant unmet need for millions of women affected by progressive hair thinning.
Addressing a Common Yet Underserved Condition
Female pattern hair loss, also known as female androgenetic alopecia, is one of the most common causes of chronic hair thinning in women. The condition affects an estimated 30 million women in the United States and becomes increasingly prevalent with age.
Unlike temporary hair shedding, female pattern hair loss is a progressive disorder characterized by gradual thinning of hair density, particularly over the crown and central scalp. Although the condition is not life-threatening, it can significantly affect self-confidence, emotional well-being, and quality of life.
Despite its prevalence, treatment options remain limited.
Current management often relies on over-the-counter topical minoxidil preparations, cosmetic approaches, or nutritional supplements that may offer inconsistent results. While oral minoxidil has increasingly been prescribed off-label by dermatologists, there is currently no FDA-approved oral prescription treatment specifically indicated for female pattern hair loss.
Veradermics is seeking to address this gap through the development of VDPHL01.
A Proprietary Extended-Release Oral Minoxidil
VDPHL01 is an investigational extended-release formulation of oral minoxidil designed to provide controlled drug delivery while supporting hair regrowth in patients with pattern hair loss.
Minoxidil has long been recognized for its ability to stimulate hair growth by improving blood flow around hair follicles, prolonging the growth phase of the hair cycle, and promoting follicular activity.
The proprietary extended-release formulation developed by Veradermics aims to optimize therapeutic exposure while maintaining an acceptable safety and tolerability profile.
The company is evaluating VDPHL01 in both male and female pattern hair loss through a comprehensive late-stage clinical development program.
Phase 2 Study Design
Study ‘207’ was an open-label Phase 2 clinical trial evaluating two dosing regimens of VDPHL01 in women with mild-to-moderate female pattern hair loss.
Participants received either:
- VDPHL01 4.5 mg once daily
- VDPHL01 4.5 mg twice daily
Treatment continued for six months, during which investigators evaluated objective measures of hair growth together with patient-reported outcomes and safety assessments.
The primary efficacy analyses focused on changes in non-vellus target area hair count (TAHC), an objective measure commonly used in clinical studies of hair loss therapies.
Researchers also assessed patient perceptions of improvement using the Androgenetic Alopecia Impact Rating Scale (AAIRS), a validated patient-reported outcome instrument measuring satisfaction with hair coverage and appearance.
Significant Improvements in Hair Growth
After six months of treatment, both dosing regimens demonstrated consistent improvements in objective hair growth.
Participants receiving once-daily therapy experienced an average increase of 22.7 non-vellus hairs per square centimeter.
Those receiving twice-daily dosing achieved a similar improvement, with an average increase of 23.3 hairs per square centimeter.
These gains indicate meaningful increases in terminal hair density across both treatment groups.
Importantly, responses appeared relatively consistent among study participants rather than being driven by only a small number of exceptional responders.
According to Veradermics, this consistency may represent an important differentiating characteristic of VDPHL01 as development progresses.
Strong Patient-Reported Outcomes
Objective improvements in hair count were accompanied by encouraging patient-reported outcomes.
Using the Androgenetic Alopecia Impact Rating Scale, investigators evaluated how participants perceived changes in their hair coverage after six months of treatment.
Among women receiving once-daily VDPHL01:
- 88.9 percent reported their hair coverage as either “improved” or “much improved.”
In the twice-daily treatment arm:
- 90.0 percent of participants reported similar levels of improvement.
These findings suggest that measured increases in hair density translated into noticeable cosmetic benefits that patients themselves recognized during treatment.
Patient-reported outcomes are considered particularly important in hair loss studies because improvements in appearance and confidence represent key treatment goals.
Early Onset of Clinical Activity
One of the notable observations from Study ‘207’ was the relatively rapid onset of therapeutic response.
Investigators observed evidence of improved hair growth as early as Month 2, the earliest scheduled efficacy assessment during the study.
At that time point:
- 67.2 percent of participants were rated by investigators as demonstrating improved hair coverage.
- 63.2 percent of participants also reported noticeable improvement in their own hair coverage.
Early visible improvement may be clinically meaningful because patients receiving hair loss therapies often discontinue treatment prematurely if benefits are not apparent during the initial months of therapy.
The ability to demonstrate measurable improvement within the first two months could potentially support better long-term treatment adherence if confirmed in larger studies.
Investigator Assessments Confirm Clinical Benefit
Clinical improvements reported by participants were also reflected in independent investigator evaluations.
At Month 6:
- 100 percent of women receiving once-daily VDPHL01 were assessed by investigators as showing improved hair coverage.
- 90 percent of women receiving twice-daily treatment were similarly rated as having experienced improvement.
The agreement between investigator assessments and patient-reported outcomes strengthens confidence that the observed increases in hair density were clinically meaningful and visible.
Favorable Safety Profile
Safety remains an important consideration in the development of oral therapies for pattern hair loss.
According to Veradermics, VDPHL01 was generally well tolerated throughout the six-month study period.
Investigators reported:
- No treatment-related serious adverse events (SAEs)
- No adverse events of special interest involving cardiac complications
- An overall safety profile consistent with previous VDPHL01 studies
Cardiovascular monitoring is particularly relevant because minoxidil was originally developed as an antihypertensive medication before its hair growth effects were recognized.
The absence of treatment-related serious cardiovascular safety findings in this study provides encouraging support for continued clinical development, although larger Phase 3 studies will be necessary to further characterize long-term safety.
Expert Perspective
Dr. Jerry Shapiro, an internationally recognized board-certified dermatologist, Director of the Hair Clinic, and Professor of Dermatology at NYU Langone Medical School, commented on the significance of the findings.
According to Dr. Shapiro, women with pattern hair loss have historically had limited prescription treatment options and have often relied on topical over-the-counter products or nutritional supplements that may not consistently achieve desired outcomes.
He stated that the results of Study ‘207’ position VDPHL01 as a potentially transformative therapy for female pattern hair loss as it advances toward becoming the first FDA-approved oral treatment specifically developed for women affected by the condition.
Company Perspective
Reid Waldman, M.D., Chief Executive Officer of Veradermics, described the Phase 2 findings as an important milestone for the company’s development program.
He noted that Study ‘207’ successfully demonstrated proof of concept using many of the same efficacy endpoints currently being evaluated in the ongoing registration-directed Phase 2/3 Study ‘306’.
According to Dr. Waldman, the consistency of the data further strengthens confidence ahead of the anticipated first-half 2027 topline readout from the pivotal female study.
He added that, if approved, VDPHL01 has the potential to become a differentiated oral treatment option capable of addressing the needs of approximately 30 million women living with female pattern hair loss while representing a substantial commercial opportunity for the company.
Broad Late-Stage Development Program
Veradermics is pursuing regulatory approval for VDPHL01 through an extensive clinical development program that includes studies in both female and male pattern hair loss.
The company is currently:
- Actively enrolling participants in Phase 2/3 Study ‘306’ evaluating female pattern hair loss.
- Anticipating topline data from Study ‘306’ during the first half of 2027.
- Continuing development in male pattern hair loss following positive topline results announced earlier this year from Study ‘302’, a registration-directed Phase 2/3 trial.
- Preparing for topline results from Study ‘304’, the company’s second Phase 3 male study, expected during the second half of 2026 after completion of enrollment announced in February.
Together, these studies form the foundation of Veradermics’ strategy to support regulatory submissions for both female and male pattern hair loss indications.
The positive topline results from Phase 2 Study ‘207’ provide encouraging evidence that VDPHL01 may become an important new therapeutic option for women experiencing pattern hair loss. The investigational extended-release oral minoxidil formulation demonstrated meaningful improvements in objective hair growth, high rates of patient-reported satisfaction, rapid onset of activity, and a favorable safety profile over six months of treatment.
While additional data from larger registration-directed studies will be needed to confirm these findings, the results strengthen the rationale for the ongoing Phase 2/3 clinical program. If future trials successfully replicate the observed efficacy and safety, VDPHL01 could become the first FDA-approved oral prescription treatment for female pattern hair loss, offering women a convenient new therapeutic option for a condition that has long remained underserved despite affecting millions worldwide.
About VDPHL01
VDPHL01 (extended-release minoxidil tablet) is a proprietary investigational, oral non-hormonal drug in Phase 3 development for pattern hair loss in both women and men. VDPHL01 leverages extended-release technology to deliver a minoxidil product with the potential for improved efficacy and safety. The proprietary extended-release formulation utilizes a gel matrix designed to deliver long-lasting, steady release of minoxidil for sustained absorption.
VDPHL01 has been shown to avoid the high peak concentrations of immediate-release oral minoxidil, while extending time above the minimum hair growth threshold to increase time for hair to grow. If approved, VDPHL01 would be the only FDA-approved oral non-hormonal treatment for pattern hair loss in both male and female patients. VDPHL01 is protected by a broad library of patents and patent applications related to the key innovations of VDPHL01. The earliest expiring patent term is 2043.
About Pattern Hair Loss
Pattern hair loss, also known as androgenetic alopecia, affects an estimated 80 million people in the United States (30 million women and 50 million men). Pattern hair loss can have a significant impact on quality of life, affecting an individual’s mental health and relationships. People with pattern hair loss often experience depression, low self-esteem, and social withdrawal.
There have been no new FDA-approved prescription medicines for pattern hair loss in nearly 30 years. In addition, current treatments include over the counter “nutraceuticals” that produce inconsistent results and contribute to high dissatisfaction among participants and healthcare providers. The prevalence of pattern hair loss and the market demand for new treatments contribute to making it the largest aesthetics market worldwide, projected to reach approximately $30 billion by 2028.
About Study ‘207’
Study ‘207’ is a multicenter Phase 2 open label study in 21 adult male and 28 adult female pattern hair loss patients to obtain proof of concept for the safety and efficacy of twelve months of treatment with VDPHL01 8.5 mg twice daily in male patients and VDPHL01 4.5 mg either once or twice daily in female patients with pattern hair loss.
About Veradermics, Inc.
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss. Veradermics aims to develop a focused portfolio of aesthetic dermatology product candidates targeting high-prevalence dermatologic conditions, with potential selective development of medical dermatology product candidates.
Its lead program, VDPHL01, is being developed as an oral, non-hormonal treatment for men and women with pattern hair loss, to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform pattern hair loss treatment. VDPHL01 is an oral, extended-release proprietary formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity.